Fluticasone propionate/salmeterol combination — Competitive Intelligence Brief

Fluticasone propionate/salmeterol combination (Fluticasone propionate/salmeterol combination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist combination. Area: Respiratory/Pulmonology.

marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol) Respiratory/Pulmonology Small molecule

Target snapshot

Fluticasone propionate/salmeterol combination (Fluticasone propionate/salmeterol combination) — GlaxoSmithKline. Fluticasone propionate is a corticosteroid that reduces airway inflammation, while salmeterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing anti-inflammatory and bronchodilator effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluticasone propionate/salmeterol combination TARGET	Fluticasone propionate/salmeterol combination	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Budesonide/formoterol Turbuhaler	Budesonide/formoterol Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Fluticasone/Salmeterol HFA	Fluticasone/Salmeterol HFA	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone/Salmeterol high dose	Fluticasone/Salmeterol high dose	Far Eastern Memorial Hospital	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone/Salmeterol Diskus	Fluticasone/Salmeterol Diskus	Johns Hopkins University	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone Propionate/Salmeterol Combination Product	Fluticasone Propionate/Salmeterol Combination Product	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol)
Fluticasone 250/formoterol 10	Fluticasone 250/formoterol 10	Research in Real-Life Ltd	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist combination class)

1. GlaxoSmithKline · 14 drugs in this class
2. Pearl Therapeutics, Inc. · 5 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. Research in Real-Life Ltd · 3 drugs in this class
5. Chiesi Farmaceutici S.p.A. · 2 drugs in this class
6. Istituto per la Ricerca e l'Innovazione Biomedica · 1 drug in this class
7. Johns Hopkins University · 1 drug in this class
8. National Jewish Health · 1 drug in this class
9. SkyePharma AG · 1 drug in this class
10. University Medical Center Groningen · 1 drug in this class